Status and phase
Conditions
Treatments
About
The purpose of this study is to learn about the safety and immune effects of a new pneumococcal vaccine in infants. The immune response is how the body's cells, tissues and organs work together to protect the body from infection. Blood samples will be used to measure the amount of antibodies produced after the vaccination. Antibodies are proteins that protect you when an unwanted germ enters the body. This will help us understand how well the new pneumococcal vaccine works. This vaccine can possibly provide protection against pneumococcal disease, which include a variety of infections caused by a specific germ, Streptococcus pneumoniae.
This study is seeking participants who are:
The participants will be assigned to one of two groups to receive 4 doses of either PG4 (the new vaccine being studied) or 20vPnC (Prevnar 20) at 2, 4, 6, and 12 to 15 months of age. The vaccines will be given as a single shot into the left thigh muscle. Participants will take part in this study for about 16 to 19 months (about 1 and a half years). During this time, participants will have 6 study clinic visits and 1 to 2 phone calls. At these study clinic visits, parent(s) or legal guardian(s) will be asked if the participant experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine. Participants in both groups will have 3 blood draws.
.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
400 participants in 4 patient groups
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal